Combination of tumour-infarction therapy and chemotherapy via the co-delivery of doxorubicin and thrombin encapsulated in tumour-targeted nanoparticles-Reference-Cited by-同舟云学术

Combination of tumour-infarction therapy and chemotherapy via the co-delivery of doxorubicin and thrombin encapsulated in tumour-targeted nanoparticles

Published:2020-06-22 Issue:7 Volume:4 Page:732-742
ISSN:2157-846X
Container-title:Nature Biomedical Engineering
language:en
Short-container-title:Nat Biomed Eng

Author:

Li Suping^ORCID,Zhang Yinlong^ORCID,Ho Shih-Hsin,Li Bozhao,Wang Meifang,Deng Xiongwei,Yang Na,Liu Guangna,Lu Zefang,Xu Junchao,Shi Quanwei,Han Jing-Yan,Zhang Lirong,Wu Yan^ORCID,Zhao Yuliang^ORCID,Nie Guangjun^ORCID

Funder

the Beijing Municipal Natural Science Foundation

the National Postdoctoral Program for Innovative Talents

the National Basic Research Plan of China

Publisher

Springer Science and Business Media LLC

Subject

Computer Science Applications,Biomedical Engineering,Medicine (miscellaneous),Bioengineering,Biotechnology

Link

http://www.nature.com/articles/s41551-020-0573-2.pdf

Reference32 articles.

1. Bieker, R. et al. Infarction of tumour vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood 113, 5019–5027 (2009).